EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences:
2024 BIO CEO & Investor Conference (Panel)
Panel Title: Reviewing Vaccine Pipeline Breakthroughs and Barriers
Date and Time: Monday, February 26, 2024 at 2:00pm ET
Location: New York, NY
IO360 Summit (Panel)
Panel Title: How to use AI to Leverage Data from Patients in the Clinic to Iterate Next Gen Immunotherapies
Date and Time: Tuesday, February 27, 2024 at 2:30pm ET
Location: New York, NY
44th Annual TD Cowen Healthcare Conference (Panel)
Panel Title: Novel I-O Corporate Panel
Date and Time: Monday, March 4, 2024 at 10:30am ET
Location: Boston, MA
World Vaccine Congress 2024 (Panel and Presentation)
Panel Title: Exploring the Future Prospects of Cancer Vaccines
Panel Date and Time: Monday, April 3, 2024 at 9:10am ET
Location: Washington, DC
Relevant events will be webcast live and available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for 30 days following each event.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
(973) 271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.03 |
| Daily Volume: | 0 |
| Market Cap: | US$3.800M |
September 30, 2024 August 13, 2024 May 09, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
